US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Halberd Corp
(OP:
HALB
)
0.0015
-0.0005 (-25.00%)
Delayed Quote
Updated: 3:24 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halberd Corp
< Previous
1
2
3
4
5
Next >
"The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach. Listen Now!
December 05, 2022
Via
ACCESSWIRE
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
December 01, 2022
Via
ACCESSWIRE
Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
November 30, 2022
Via
ACCESSWIRE
Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast Cancer
November 17, 2022
Via
ACCESSWIRE
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
November 14, 2022
Via
ACCESSWIRE
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast
October 27, 2022
Via
ACCESSWIRE
Halberd Laser Therapy Eliminates over 90% of Multiple Antibiotic Resistant Bacteria in Minutes
October 18, 2022
Via
ACCESSWIRE
Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum
October 12, 2022
Via
ACCESSWIRE
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
September 27, 2022
Via
ACCESSWIRE
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
September 27, 2022
Jackson Center, Pennsylvania--(Newsfile Corp. - September 27, 2022) - Halberd Corporation (OTC Pink: HALB) entered into a strategic alliance with AI...
Via
Newsfile
Topics
Animal Testing
Artificial Intelligence
Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein
August 23, 2022
Via
ACCESSWIRE
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
August 04, 2022
Via
ACCESSWIRE
Halberd Corporation Discusses OTCQB Uplisting and Growing List of Proprietary Technologies with The Stock Day Podcast
July 28, 2022
Phoenix, Arizona--(Newsfile Corp. - July 28, 2022) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB), a publicly...
Via
Newsfile
Topics
Intellectual Property
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
July 20, 2022
Via
ACCESSWIRE
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
July 20, 2022
JACKSON CENTER, PA / ACCESSWIRE / July 20, 2022 / Halberd Corporation (OTC PINK:HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
July 14, 2022
Boosts Effectiveness of Commercial Covid Antibodies by 45%
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Halberd Corporation Update, CEO Letter and 2022 Expectations
July 12, 2022
Q2 Accomplishments and a Look to the Future
From
Halberd Corporation
Via
AccessWire
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
June 21, 2022
JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) announced the creation of...
From
Halberd Corporation
Via
AccessWire
Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
June 08, 2022
JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
May 24, 2022
JACKSON CENTER, PA / ACCESSWIRE / May 24, 2022 / Halberd Corporation (OTC PINK:HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Halberd Engages Professional Firm to Proceed with FDA Filings
May 18, 2022
JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug...
From
Halberd Corporation
Via
AccessWire
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB
May 12, 2022
JACKSON CENTER, PA / ACCESSWIRE / May 12, 2022 / Halberd Corporation (OTC PINK:HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Regulatory Compliance
Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases
April 29, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Halberd Corporation
Via
AccessWire
Halberd CEO Letter
April 25, 2022
Q1 Accomplishments and Q2 Plans JACKSON CENTER, PA / ACCESSWIRE / April 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) This past quarter has witnessed some very...
From
Halberd Corporation
Via
AccessWire
Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics
April 18, 2022
JACKSON CENTER, PA / ACCESSWIRE / April 18, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease...
From
Halberd Corporation
Via
AccessWire
Topics
Animal Testing
Halberd Entering the Medical Metaverse(TM)
April 11, 2022
JACKSON CENTER, PA / ACCESSWIRE / April 11, 2022 / Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT's) to monetize certain...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression
April 04, 2022
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to...
From
Halberd Corporation
Via
AccessWire
Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans
March 16, 2022
JACKSON CENTER, PA / ACCESSWIRE / March 16, 2022 / Halberd Corporation (OTC PINK:HALB) announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target...
From
Halberd Corporation
Via
AccessWire
Halberd Expands Its Technical Expertise with the Addition of Microbiology Professor
March 08, 2022
JACKSON CENTER, PA / ACCESSWIRE / March 8, 2022 / Halberd Corporation (OTC PINK:HALB) is pleased to announce Youngstown State University's (YSU) Dr. Chester R. Cooper has joined its technical team. Dr....
From
Halberd Corporation
Via
AccessWire
Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
March 01, 2022
Outperforms Approved COVID Antibodies JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation's (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding...
From
Halberd Corporation
Via
AccessWire
< Previous
1
2
3
4
5
Next >
